FDA places partial hold on Molecular Templates’ Phase I trial

FDA places partial hold on Molecular Templates’ Phase I trial

Source: 
Clinical Trials Arena
snippet: 

The US Food and Drug Administration (FDA) has placed a partial hold on Molecular Templates’ Phase I trial of MT-0169 in patients with relapsed multiple myeloma.

The partial hold is based on the previously disclosed cardiac adverse events that occurred in two participants who received MT-0169 at 50mcg/kg dose.